Welcome to our dedicated page for Achieve Life Sciences SEC filings (Ticker: ACHV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Achieve Life Sciences, Inc. (Nasdaq: ACHV) SEC filings page brings together the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. Achieve describes itself as a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment of nicotine dependence, and its filings provide formal detail on this business focus, its capital structure, and material events.
Investors reviewing ACHV’s filings can find current reports on Form 8-K that disclose items such as quarterly financial results, executive leadership changes, material definitive agreements, and equity offerings. For example, recent 8-K filings reference press releases announcing financial results, the appointment or resignation of senior officers, and an underwriting agreement for an offering of common stock and warrants under an effective shelf registration statement.
In addition to 8-Ks, Achieve files periodic reports such as Forms 10-K and 10-Q (not reproduced here) that typically include more extensive discussion of its cytisinicline clinical program, risk factors, and financial condition. These documents are central for understanding how the company presents its late-stage development activities, including the FDA’s acceptance of its New Drug Application for cytisinicline for smoking cessation and the status of its vaping cessation program.
On Stock Titan, ACHV filings are updated as they are made available through EDGAR, and AI-powered tools can help summarize lengthy reports, highlight key sections, and surface information about topics such as clinical trial progress, financing arrangements, and governance changes. Users can also review insider and executive-related disclosures reported via Forms 3, 4, and 5 when available, to see transactions and compensatory arrangements that Achieve reports for its officers and directors.
By using this page, readers can quickly locate Achieve’s official SEC documents and use AI-generated insights to better understand how the company reports its operations, cytisinicline development, and material corporate events in a regulatory context.
Mark K. Oki, Chief Financial Officer of Achieve Life Sciences, Inc. (ACHV), reported receipt of 168,000 performance restricted stock units (PRSUs) on 09/04/2025. The filing states these PRSUs were previously disclosed on December 9, 2024 and were earned after the Compensation Committee certified achievement of specified performance criteria. Each PRSU converts into one share of common stock at settlement. The reported award shows an exercise/settlement reference date of 12/06/2028 and a reported price of $0. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Oki on 09/08/2025.
Richard Stewart, a director and executive officer of Achieve Life Sciences, Inc. (ACHV), reported two awards of Performance Restricted Stock Units (PRSUs) on 09/04/2025. The filing shows acquisition of 140,000 PRSUs (linked to common stock) and 157,500 PRSUs, each representing a contingent right to one share at settlement. The PRSUs were previously reported as earned when performance targets were certified by the Compensation Committee. The awards list future settlement/exercise dates of 01/22/2028 and 01/13/2029 and show 0 shares beneficially owned following the transactions, indicating these remain contingent/subject to settlement terms.
Jerry Wan, identified as an officer (Principal Accounting Officer), reported transactions in Achieve Life Sciences, Inc. (ACHV) dated 09/04/2025. He received 34,100 shares of common stock upon settlement of performance restricted stock units (PRSUs) and sold 14,070 shares to satisfy tax withholding, at a weighted-average price of $2.77 per share (sales ranged from $2.68 to $2.88).
The filing shows PRSUs that were previously reported as earned by the Compensation Committee: one group of 24,500 PRSUs tied to milestone-based vesting and another group of 9,600 PRSUs with a vesting range of 0%–100% depending on future milestones. After these transactions the reporting person beneficially owned 46,764 shares.
Thomas B. King, a director of Achieve Life Sciences, Inc. (ACHV), settled performance-based equity and received 455,000 shares of common stock on September 4, 2025. These shares resulted from performance restricted stock units (PRSUs) that were previously reported as earned after the Compensation Committee certified achievement of certain performance criteria. To satisfy tax withholding obligations associated with the net settlement, 139,858 shares were sold at weighted-average prices between $2.68 and $2.88 per share, generating a reported sale price of $2.77 per share. After settlement and the withholding sale, the reporting person beneficially owned 315,142 shares directly.
Insider transactions by Cindy Jacobs at Achieve Life Sciences (ACHV) show settlement of performance restricted stock units into common stock and a small sale to cover tax withholding. On 09/04/2025 Ms. Jacobs had 110,000 shares acquired upon settlement of PRSUs and separately sold 27,629 shares at a weighted average price between $2.68 and $2.88 to satisfy income tax withholding obligations. Following these transactions she beneficially owned 115,585 shares of common stock. The filing states the PRSUs were previously reported as earned after Compensation Committee certification and that some PRSUs vest subject to milestone conditions, with certain awards exercisable or settling on specified future dates.
Achieve Life Sciences insider report: Jaime Xinos, the company's Chief Commercial Officer and a director, reported transactions dated 09/04/2025. He received 69,000 shares of common stock upon settlement of performance restricted stock units (PRSUs) and the issuer sold 20,854 shares to cover income tax withholding at a weighted average price of $2.77 per share. After these transactions he beneficially owned 74,432 shares. The Form 4 also shows outstanding PRSUs: 49,000 that vest upon achievement of certain milestones (settlement date tied to 01/22/2028) and 20,000 PRSUs with a measurement period extending to 01/28/2035 that may vest 0%–100% depending on performance. The form was filed by an attorney-in-fact on 09/08/2025.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh report beneficial ownership of 4,918,822 shares of Achieve Life Sciences (ACHV), representing 9.9% of the outstanding common stock. The reporting persons directly hold 3,504,333 shares and also hold warrants exercisable in form for up to 2,804,333 shares, but the warrants contain a 9.9% exercise cap so only 1,414,489 warrant shares are currently exercisable and included in the reported total. The percentage calculation uses the issuer's stated outstanding share count of 49,685,072. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
FAQ
What is the current stock price of Achieve Life Sciences (ACHV)?
What is the market cap of Achieve Life Sciences (ACHV)?
